Efficacy and Safety of Antithrombotic Therapy with Non-vitamin K Antagonist Oral Anticoagulants After Transcatheter Aortic Valve Replacement: a Systematic Review and Meta-analysis

Overview

Journal Ther Adv Chronic Dis

Publisher Sage Publications

Date 2021 Nov 22

PMID 34804464

Citations 1

Authors

Qing An

Shuwen Su

Yan Tu

Lingfeng Gao

Gaopeng Xian

Yujia Bai

Qiong Zhan

Xingbo Xu

Dingli Xu

Qingchun Zeng

Affiliations

Soon will be listed here.

Abstract

Objective: A meta-analysis was performed to compare the efficacy and safety of antithrombotic therapy with non-vitamin K antagonist oral anticoagulants (NOACs) standard care in patients after successful transcatheter aortic valve replacement (TAVR).

Methods: A systematic search of PubMed, Cochrane Central Register of Controlled Trials, and EMBASE databases and ClinicalTrials.gov website (through 21 October 2020) was performed. Risk ratios (RRs) with 95% confidence intervals (CIs) for all outcomes were calculated using random-effects models.

Results: Twelve studies (two studies were randomized controlled trials) comprising 6943 patients were included (5299 had indications for oral anticoagulation (OAC) and 1644 had none). No significant differences were found between NOACs and the standard care in the incidences of all stroke, a composite endpoint, and major/life-threatening bleeding. NOACs were associated with lower all-cause mortality than vitamin K antagonists (VKAs) in post-TAVR patients with indications for OAC after more than 1 year of follow-up [RR = 0.64; 95% CI, (0.42, 0.96); = 0.03], whereas NOACs exhibited poor outcomes than antiplatelet therapy (APT) in patients without indications for OAC [RR = 1.66; 95% CI, (1.12, 2.45); = 0.01]. In the prevention of valve thrombosis, NOACs and VKAs were not significantly different in patients with indications for OAC [RR = 0.66; 95% CI, (0.24, 1.84); = 0.43], whereas NOACs were better than APT in patients without indications for OAC [RR = 0.19; 95% CI, (0.04, 0.83); = 0.03].

Conclusions: In patients with indications for OAC, post-TAVR antithrombotic therapy with NOACs was more favorable due to its lower all-cause mortality after more than 1 year of follow-up. In those without indications for OAC, NOACs presented poorer outcomes due to its higher all-cause mortality.

Citing Articles

Non-vitamin K antagonist oral anticoagulants (NOACs) after transcatheter aortic valve replacement (TAVR): a network meta-analysis.

Al Said S, Kaier K, Nury E, Alsaid D, Gibson C, Bax J Cochrane Database Syst Rev. 2025; 2:CD013745.

PMID: 39991882 PMC: 11848970. DOI: 10.1002/14651858.CD013745.pub2.

Antithrombotic Therapy Following Transcatheter Aortic Valve Replacement.

Granger C, Guedeney P, Collet J J Clin Med. 2022; 11(8).

PMID: 35456283 PMC: 9031701. DOI: 10.3390/jcm11082190.

References

Piccolo R, Pilgrim T, Franzone A, Valgimigli M, Haynes A, Asami M . Frequency, Timing, and Impact of Access-Site and Non-Access-Site Bleeding on Mortality Among Patients Undergoing Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2017; 10(14):1436-1446. DOI: 10.1016/j.jcin.2017.04.034. View

Baumgartner H, Falk V, Bax J, De Bonis M, Hamm C, Holm P . 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017; 38(36):2739-2791. DOI: 10.1093/eurheartj/ehx391. View

Otto C, Kumbhani D, Alexander K, Calhoon J, Desai M, Kaul S . 2017 ACC Expert Consensus Decision Pathway for Transcatheter Aortic Valve Replacement in the Management of Adults With Aortic Stenosis: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2017; 69(10):1313-1346. DOI: 10.1016/j.jacc.2016.12.006. View

Van Mieghem N, Schipper M, Ladich E, Faqiri E, van der Boon R, Randjgari A . Histopathology of embolic debris captured during transcatheter aortic valve replacement. Circulation. 2013; 127(22):2194-201. DOI: 10.1161/CIRCULATIONAHA.112.001091. View

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax J, Blomstrom-Lundqvist C . 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the.... Eur Heart J. 2020; 42(5):373-498. DOI: 10.1093/eurheartj/ehaa612. View

Vranckx P, Windecker S, Welsh R, Valgimigli M, Mehran R, Dangas G . Thrombo-embolic prevention after transcatheter aortic valve implantation. Eur Heart J. 2017; 38(45):3341-3350. DOI: 10.1093/eurheartj/ehx390. View

Lindman B, Clavel M, Mathieu P, Iung B, Lancellotti P, Otto C . Calcific aortic stenosis. Nat Rev Dis Primers. 2016; 2():16006. PMC: 5127286. DOI: 10.1038/nrdp.2016.6. View

Stenflo J, Fernlund P, Egan W, Roepstorff P . Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci U S A. 1974; 71(7):2730-3. PMC: 388542. DOI: 10.1073/pnas.71.7.2730. View

Chakravarty T, Sondergaard L, Friedman J, De Backer O, Berman D, Kofoed K . Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017; 389(10087):2383-2392. DOI: 10.1016/S0140-6736(17)30757-2. View

10.

Mangieri A, Montalto C, Poletti E, Sticchi A, Crimi G, Giannini F . Thrombotic Versus Bleeding Risk After Transcatheter Aortic Valve Replacement: JACC Review Topic of the Week. J Am Coll Cardiol. 2019; 74(16):2088-2101. DOI: 10.1016/j.jacc.2019.08.1032. View

11.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

12.

Kearon C, Akl E, Ornelas J, Blaivas A, Jimenez D, Bounameaux H . Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2):315-352. DOI: 10.1016/j.chest.2015.11.026. View

13.

Van Mieghem N, Unverdorben M, Hengstenberg C, Mollmann H, Mehran R, Lopez-Otero D . Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. N Engl J Med. 2021; 385(23):2150-2160. DOI: 10.1056/NEJMoa2111016. View

14.

Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J . Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003; 73(9):712-6. DOI: 10.1046/j.1445-2197.2003.02748.x. View

15.

Schurgers L, Aebert H, Vermeer C, Bultmann B, Janzen J . Oral anticoagulant treatment: friend or foe in cardiovascular disease?. Blood. 2004; 104(10):3231-2. DOI: 10.1182/blood-2004-04-1277. View

16.

Sannino A, Hahn R, Leipsic J, Mack M, Grayburn P . Meta-analysis of Incidence, Predictors and Consequences of Clinical and Subclinical Bioprosthetic Leaflet Thrombosis After Transcatheter Aortic Valve Implantation. Am J Cardiol. 2020; 132:106-113. DOI: 10.1016/j.amjcard.2020.07.018. View

17.

Ferland G . The discovery of vitamin K and its clinical applications. Ann Nutr Metab. 2012; 61(3):213-8. DOI: 10.1159/000343108. View

18.

Otto C, Nishimura R, Bonow R, Carabello B, Erwin 3rd J, Gentile F . 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020; 143(5):e72-e227. DOI: 10.1161/CIR.0000000000000923. View

19.

Weijs B, Blaauw Y, Rennenberg R, Schurgers L, Timmermans C, Pison L . Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J. 2011; 32(20):2555-62. DOI: 10.1093/eurheartj/ehr226. View

20.

Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler K . 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021; 23(10):1612-1676. PMC: 11636576. DOI: 10.1093/europace/euab065. View